Citation Impact
Citing Papers
Identification of Subtypes in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome
2010
Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging
2023 Standout
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 Standout
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
2009 Standout
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
2014
Redox regulation in tumor cell epithelial–mesenchymal transition: molecular basis and therapeutic strategy
2017
Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
2008
Preoperative assessment of HER-2/neu status in breast carcinoma: The role of quantitative real-time PCR on core-biopsy specimens
2009
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Hypoxia Selectively Enhances Integrin α5β1 Receptor Expression in Breast Cancer to Promote Metastasis
2017 StandoutNobel
PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data
2014
RNAscope
2011 Standout
Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
2015
Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model
2008
Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis
2015 Standout
Metformin-like antidiabetic, cardio-protective and non-glycemic effects of naringenin: Molecular and pharmacological insights
2017
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
The biology and management of non-small cell lung cancer
2018 StandoutNature
Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer
2010
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy
2021 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Network medicine: a network-based approach to human disease
2010 Standout
uPA AND PAI-1 In Breast Cancer: Review Of Their Clinical Utility And Current Validation In The ProspectivE NNBC-3 TRIAL
2008
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma
2017
Biological processes, properties and molecular wiring diagrams of candidate low-penetrance breast cancer susceptibility genes
2008
Precision medicine in cholangiocarcinoma
2018
Green tea polyphenols: biology and therapeutic implications in cancer
2007
Prognostic Value of Ki67 Expression After Short-Term Presurgical Endocrine Therapy for Primary Breast Cancer
2007
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention
2017
Oxidative Stress in Cancer
2020 Standout
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications
2011 Standout
GOBO: Gene Expression-Based Outcome for Breast Cancer Online
2011
The CDK inhibitors in cancer research and therapy
2011
Macrophage M1/M2 polarization
2020 Standout
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
The PI3K Pathway in Human Disease
2017 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
2020 Standout
HPLC Purification of In Vitro Transcribed Long RNA
2012 StandoutNobel
The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy
2019 StandoutNobel
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
2015
Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response
2018 StandoutNobel
Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?
2018
Akt Signaling in Macrophage Polarization, Survival, and Atherosclerosis
2019
Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1α to promote cell-cycle progression
2014 StandoutNobel
Targeting ALK: Precision Medicine Takes on Drug Resistance
2017
Molecular docking studies on the interaction of NCI anticancer analogues with human Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit
2019
Breast Cancer Treatment
2019 Standout
An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study
2020 Standout
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues
2006
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Important Flavonoids and Their Role as a Therapeutic Agent
2020 Standout
Works of Patrick Urban being referenced
Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2
2005
Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients
2006
Increased Expression of Urokinase-Type Plasminogen Activator mRNA Determines Adverse Prognosis in ErbB2-Positive Primary Breast Cancer
2006
Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome
2007
Comparison of gene expression profiles in core biopsies and corresponding surgical breast cancer samples
2006
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)
2016
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
2017
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
2016
Genetic landscape of patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study
2021
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
2017
Abstract OT2-6-08: Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer – NeoPHOEBE
2013
Abstract P6-11-08: A multicenter, open-label Ph IB/II study of BEZ235, an oral dual PI3K/mTOR inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer
2012
Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment.
2013